In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration

David S Alberts, Laurie Young, Nancy Mason, Sydney E. Salmon

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

High-dose intraperitoneal chemotherapy is a current developmental approach in the treatment of advanced ovarian cancer. Considerable pharmacologic data have been obtained on the intraperitoneal · time product for a number of agents administered by this route. We used the human tumor cloning assay (HTCA) to compare the activities of both standard and experimental agents used for intraperitoneal treatment. In vitro dose-survival curves were constructed for each drug over a two-log range of concentrations using fresh ovarian cancers from more than 50 patients. The mean concentration · time product (CXT) achievable in the intraperitoneal space after high-dose intraperitoneal drug administration was divided by the corresponding ID50 value (concentration of drug in vitro associated with 50% survival of tumor colonies) for each agent to calculate in vivo CXT: in vitro ID50 ratios. Using this approach, the standard agents, melphalan, cisplatin, and 5-FU were predicted to have similar efficacies by intraperitoneal administration, but doxorubicin and mitomycin were significantly inferior. Of the drugs tested, the new agent mitoxantrone was associated with the most favorable CXT to ID50 ratio and is, therefore, predicted to be particularly promising for intraperitoneal administration.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalSeminars in Oncology
Volume12
Issue number3 SUPPL. 4
StatePublished - 1985

Fingerprint

Drug Evaluation
Ovarian Neoplasms
Pharmaceutical Preparations
Mitoxantrone
Melphalan
Survival
Mitomycin
Fluorouracil
Doxorubicin
Cisplatin
Organism Cloning
Neoplasms
Drug Therapy
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. / Alberts, David S; Young, Laurie; Mason, Nancy; Salmon, Sydney E.

In: Seminars in Oncology, Vol. 12, No. 3 SUPPL. 4, 1985, p. 38-42.

Research output: Contribution to journalArticle

@article{067ce68504c24e0d84e8a5f47c2dea17,
title = "In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration",
abstract = "High-dose intraperitoneal chemotherapy is a current developmental approach in the treatment of advanced ovarian cancer. Considerable pharmacologic data have been obtained on the intraperitoneal · time product for a number of agents administered by this route. We used the human tumor cloning assay (HTCA) to compare the activities of both standard and experimental agents used for intraperitoneal treatment. In vitro dose-survival curves were constructed for each drug over a two-log range of concentrations using fresh ovarian cancers from more than 50 patients. The mean concentration · time product (CXT) achievable in the intraperitoneal space after high-dose intraperitoneal drug administration was divided by the corresponding ID50 value (concentration of drug in vitro associated with 50{\%} survival of tumor colonies) for each agent to calculate in vivo CXT: in vitro ID50 ratios. Using this approach, the standard agents, melphalan, cisplatin, and 5-FU were predicted to have similar efficacies by intraperitoneal administration, but doxorubicin and mitomycin were significantly inferior. Of the drugs tested, the new agent mitoxantrone was associated with the most favorable CXT to ID50 ratio and is, therefore, predicted to be particularly promising for intraperitoneal administration.",
author = "Alberts, {David S} and Laurie Young and Nancy Mason and Salmon, {Sydney E.}",
year = "1985",
language = "English (US)",
volume = "12",
pages = "38--42",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 4",

}

TY - JOUR

T1 - In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration

AU - Alberts, David S

AU - Young, Laurie

AU - Mason, Nancy

AU - Salmon, Sydney E.

PY - 1985

Y1 - 1985

N2 - High-dose intraperitoneal chemotherapy is a current developmental approach in the treatment of advanced ovarian cancer. Considerable pharmacologic data have been obtained on the intraperitoneal · time product for a number of agents administered by this route. We used the human tumor cloning assay (HTCA) to compare the activities of both standard and experimental agents used for intraperitoneal treatment. In vitro dose-survival curves were constructed for each drug over a two-log range of concentrations using fresh ovarian cancers from more than 50 patients. The mean concentration · time product (CXT) achievable in the intraperitoneal space after high-dose intraperitoneal drug administration was divided by the corresponding ID50 value (concentration of drug in vitro associated with 50% survival of tumor colonies) for each agent to calculate in vivo CXT: in vitro ID50 ratios. Using this approach, the standard agents, melphalan, cisplatin, and 5-FU were predicted to have similar efficacies by intraperitoneal administration, but doxorubicin and mitomycin were significantly inferior. Of the drugs tested, the new agent mitoxantrone was associated with the most favorable CXT to ID50 ratio and is, therefore, predicted to be particularly promising for intraperitoneal administration.

AB - High-dose intraperitoneal chemotherapy is a current developmental approach in the treatment of advanced ovarian cancer. Considerable pharmacologic data have been obtained on the intraperitoneal · time product for a number of agents administered by this route. We used the human tumor cloning assay (HTCA) to compare the activities of both standard and experimental agents used for intraperitoneal treatment. In vitro dose-survival curves were constructed for each drug over a two-log range of concentrations using fresh ovarian cancers from more than 50 patients. The mean concentration · time product (CXT) achievable in the intraperitoneal space after high-dose intraperitoneal drug administration was divided by the corresponding ID50 value (concentration of drug in vitro associated with 50% survival of tumor colonies) for each agent to calculate in vivo CXT: in vitro ID50 ratios. Using this approach, the standard agents, melphalan, cisplatin, and 5-FU were predicted to have similar efficacies by intraperitoneal administration, but doxorubicin and mitomycin were significantly inferior. Of the drugs tested, the new agent mitoxantrone was associated with the most favorable CXT to ID50 ratio and is, therefore, predicted to be particularly promising for intraperitoneal administration.

UR - http://www.scopus.com/inward/record.url?scp=0022351998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022351998&partnerID=8YFLogxK

M3 - Article

C2 - 3931226

AN - SCOPUS:0022351998

VL - 12

SP - 38

EP - 42

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 4

ER -